February 7, 2015
U.S. FDA Approves IMBRUVICA® (ibrutinib) for the Treatment of Waldenström’s Macroglobulinemia: First FDA-Approved Therapy for This Disease
Read More
October 24, 2014
IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom’s macroglobulinemia
Read More
X